Previous 10 | Next 10 |
2023-10-03 16:48:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were up more than 13% as of 3 p.m. on Tuesday. The stock bounced back strongly after hitting its 52-week low at $12.94 on Monday. The healthcare stock is down more than 37% so far this year. Kymera is a clinical...
KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023 Fast Track designation can potentially accelerate KT-333’s development path for the treatment of R/R Cutaneous T...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company’s management team...
2023-08-09 16:21:48 ET Summary Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug Designation for KT-253, a potential treatment for acute myeloid leukemia, boosting its prospects. ...
2023-08-06 07:21:39 ET Summary Kymera Therapeutics is a clinical-stage developmental firm focused on developing small molecule therapeutics to degrade disease-causing proteins. Analysts are mixed on the shares and the stock has a large short position in the equity currently. T...
2023-08-06 02:55:21 ET Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 03, 2023 09:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Justine Koenigsberg - VP, IR Confe...
2023-08-03 07:30:22 ET Kymera Therapeutics press release ( NASDAQ: KYMR ): Q2 GAAP EPS of -$0.67 beats by $0.06 . Revenue of $16.51M (+43.4% Y/Y) beats by $2.77M . For further details see: Kymera Therapeutics GAAP EPS of -$0.67 beats by $0.06, revenue of ...
KT-474/SAR444656 (IRAK4) Phase 2 trials for both hidradenitis suppurativa (HS) and atopic dermatitis (AD) planned to start in 4Q23 by partner Sanofi Phase 1 oncology trials for KT-253 (MDM2), KT-333 (STAT3), and KT-413 (IRAKIMiD) degraders ongoing, with clinical ...
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2023 financial results on Augu...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...